Lower complement C1q levels in first-episode psychosis and in schizophrenia.

Cerebrospinal fluid Complement C1q Complement C4 Schizophrenia

Journal

Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478

Informations de publication

Date de publication:
30 Jan 2024
Historique:
received: 27 09 2023
revised: 22 12 2023
accepted: 25 01 2024
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 1 2 2024
Statut: aheadofprint

Résumé

Recent evidence has implicated complement component (C) 4A in excessive elimination of synapses in schizophrenia. C4A is believed to contribute to physiological synapse removal through signaling within the C1q initiated classical activation axis of the complement system. So far, a potential involvement of C1q in the pathophysiology of schizophrenia remains unclear. In this study, we first utilized large-scale gene expression datasets (n = 586 patients with schizophrenia and n = 986 controls) to observe lower C1QA mRNA expression in prefrontal cortex tissue of individuals with schizophrenia (P = 4.8x10

Identifiants

pubmed: 38301948
pii: S0889-1591(24)00231-9
doi: 10.1016/j.bbi.2024.01.219
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Marja Koskuvi (M)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Susmita Malwade (S)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Jessica Gracias Lekander (J)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Elin Hörbeck (E)

The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Department of Psychotic Disorders, Sahlgrenska University Hospital, Mölndal, Sweden.

Sanna Bruno (S)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Jessica Holmen Larsson (J)

The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.

Aurimantas Pelanis (A)

Department of Anesthesiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Anniella Isgren (A)

The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Department of Psychotic Disorders, Sahlgrenska University Hospital, Mölndal, Sweden.

Anneli Goulding (A)

Department of Psychotic Disorders, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychology, University of Gothenburg, Gothenburg, Sweden.

Helena Fatouros-Bergman (H)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden.
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Martin Schalling (M)

Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital Solna, 171 76 Stockholm, Sweden.

Fredrik Piehl (F)

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

Sophie Erhardt (S)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Mikael Landen (M)

The Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Simon Cervenka (S)

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden; Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.

Funda Orhan (F)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Carl M Sellgren (CM)

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden. Electronic address: carl.sellgren@ki.se.

Classifications MeSH